ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
-1,03%
Bitcoin
62 813,76
6,25%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Vaxxinity Inc (VAXX)

  7. Vaxxinity Inc (VAXX) Actualités

VAXX Vaxxinity Inc

0,1298
0,0256 (24,57%)
Après les heures de négociation
Dernière mise à jour : 00:04:37
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Vaxxinity Inc VAXX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,0256 24,57% 0,1298 00:04:37
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,1486 0,1222 0,1488 0,1411 0,1042
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
20/4/202400:53GLOBEVaxxinity Issues Shareholder Letter
19/4/202422:27GLOBEVaxxinity Announces Intention to Voluntarily Delist and..
28/3/202414:23GLOBEVaxxinity to Present Clinical Data at the Annual Academy of..
27/3/202421:41GLOBEVaxxinity Reports Fourth Quarter and Full-Year 2023..
07/3/202416:32GLOBEVaxxinity Announces Positive Target Engagement Data from..
15/2/202422:15EDGAR2Form 8-K - Current report
15/2/202414:00GLOBEVaxxinity’s Cholesterol Vaccine Candidate Successfully..
13/2/202414:00GLOBEVaxxinity to Present Clinical and Preclinical Pipeline Data..
12/2/202423:02EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202423:02EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
30/1/202414:00GLOBEVaxxinity Announces Research Collaboration on Active..
18/1/202414:00GLOBEVaxxinity Announces Collaboration on Space Medicine Research..
03/1/202414:00GLOBEVaxxinity to Present at the 2024 J.P. Morgan Healthcare..
01/12/202316:30EDGAR2Form 8-K - Current report
30/11/202323:03EDGAR2Form 144 - Report of proposed sale of securities
30/11/202322:54EDGAR2Form 144 - Report of proposed sale of securities
29/11/202323:13EDGAR2Form 144 - Report of proposed sale of securities
29/11/202323:10EDGAR2Form 144 - Report of proposed sale of securities
21/11/202322:21EDGAR2Form 144 - Report of proposed sale of securities
21/11/202322:20EDGAR2Form 144 - Report of proposed sale of securities
14/11/202300:50GLOBEVaxxinity to Present at Upcoming November Medical and..
08/11/202314:30GLOBEVaxxinity Reports Third Quarter 2023 Financial Results and..
08/11/202313:53EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202321:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202322:33EDGAR2Form 144 - Report of proposed sale of securities
04/10/202322:24EDGAR2Form 144 - Report of proposed sale of securities
28/9/202322:15EDGAR2Form 8-K - Current report
22/9/202322:16EDGAR2Form 144 - Report of proposed sale of securities
22/9/202322:12EDGAR2Form 144 - Report of proposed sale of securities
29/8/202314:00GLOBEVaxxinity to Present at Upcoming Investor Conferences in..
21/8/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
10/8/202314:00GLOBEVaxxinity Announces Publication of UB-311 Safety,..
09/8/202314:00GLOBEVaxxinity Reports Second Quarter 2023 Financial Results and..
09/8/202313:31EDGAR2Form S-3 - Registration statement under Securities Act of..
09/8/202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
27/7/202322:30GLOBEVaxxinity Appoints Peter Powchik, M.D., to Executive Vice..
27/7/202322:04EDGAR2Form 8-K - Current report
17/7/202314:00GLOBEVaxxinity Demonstrates Target Engagement of Toxic..
22/6/202314:00GLOBEVaxxinity Announces UB-312 Successfully Met Primary..
09/5/202314:00GLOBEVaxxinity Reports First Quarter 2023 Financial Results and..

Dernières Valeurs Consultées

NASDAQ
VAXX
Vaxxinity
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés